A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancer.

While there was no significant difference between induction treatment dose intensity for cisplatin and pemetrexed ( Table 4 ), there were seven patients in B and 16 in A who received pemetrexed maintenance, demonstrating a clear trend for a higher usage of pemetrexed maintenance in arm A (X 2 -test, p = 0.14).

also in 19,460 other papers